Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,197 matching trials from the live ClinicalTrials.gov search.

Filters: Durham, North Carolina Clear all

Conditions: Sarcoidosis-associated Pulmonary Hypertension
Interventions: Selexipag, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Indianapolis, Indiana • New Orleans, Louisiana • New York, New York + 5 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 51
States / cities: Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 46 more

Conditions: Acute Myeloid Leukemia
Interventions: Alvocidib, Cytarabine, Mitoxantrone; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 26
States / cities: Scottsdale, Arizona • Los Angeles, California • San Diego, California + 23 more

Conditions: Chronic GVHD
Interventions: Sirolimus + calcineurin inhibitor + prednisone, Sirolimus + prednisone; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Not listed
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 31
States / cities: Duarte, California • La Jolla, California • Stanford, California + 27 more

Conditions: Myasthenia Gravis, Generalized
Interventions: zilucoplan (RA101495), Placebo; Drug
Lead sponsor: Ra Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 37
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more

Conditions: Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions: Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more

Conditions: Breast Cancer
Interventions: Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression; Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 3,960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 1240
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 813 more

Conditions: Sickle Cell Disease
Interventions: Single blood transfusion, Standard care; Biological · Behavioral
Lead sponsor: Carelon Research; Other
Eligibility: 2 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 24
States / cities: Oakland, California • Wilmington, Delaware • Washington D.C., District of Columbia + 14 more

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: AC2993, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 126
States / cities: Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more

Conditions: Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Interventions: cisplatin, ifosfamide, paclitaxel, vinblastine; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 78
States / cities: Anniston, Alabama • La Jolla, California • Los Angeles, California + 57 more

Conditions: FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR3 Gene Amplification, FGFR3 Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions: Docetaxel, FGFR Inhibitor AZD4547, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 25 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1083
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 672 more

Conditions: Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Extraskeletal Osteosarcoma, Fibrohistiocytic Neoplasm, Fibrosarcoma, Inflammatory Myofibroblastic Tumor, Intimal Sarcoma, Leiomyosarcoma, Liposarcoma, Liver Embryonal Sarcoma, Low Grade Fibromyxoid Sarcoma, Low Grade Myofibroblastic Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Skin Granular Cell Tumor, Malignant Triton Tumor, Mesenchymal Chondrosarcoma, Myxofibrosarcoma, Myxoid Chondrosarcoma, Myxoinflammatory Fibroblastic Sarcoma, Nerve Sheath Neoplasm, PEComa, Pericytic Neoplasm, Plexiform Fibrohistiocytic Tumor, Sclerosing Epithelioid Fibrosarcoma, Skin Glomus Tumor, Stage IB Soft Tissue Sarcoma AJCC v7, Stage IIB Soft Tissue Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Interventions: Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide, Pazopanib, Pazopanib Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery; Drug · Radiation · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 365
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more

Conditions: Behavior, Health, Child Obesity
Interventions: Greenlight Plus, Greenlight; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: Up to 21 Days
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 6
States / cities: Stanford, California • Coral Gables, Florida • New York, New York + 3 more

Conditions: Prostate Cancer, Sexual Dysfunction
Interventions: Tadalafil, Placebo; Drug · Other
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 242 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 183
States / cities: Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 151 more

Conditions: Metastatic Ewing Sarcoma
Interventions: Vincristine, Doxorubicin, Cyclophosphamide, Ifosfamide, Actinomycin, Irinotecan, Cabozantinib, Topotecan, Temozolomide, Etoposide, Liposomal doxorubicin; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 1 Year and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 21
States / cities: Birmingham, Alabama • Phoenix, Arizona • Hartford, Connecticut + 17 more

Conditions: Gout
Interventions: placebo, pegloticase; Other · Biological
Lead sponsor: Savient Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 50
States / cities: Birmingham, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 45 more

Conditions: Chronic Plaque Psoriasis
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 6,065 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2023
U.S. locations: 222
States / cities: Birmingham, Alabama • Daphne, Alabama • Huntsville, Alabama + 173 more

Conditions: Gestational Diabetes Mellitus
Interventions: Childbirth; Procedure
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 8
States / cities: Birmingham, Alabama • New Orleans, Louisiana • Chapel Hill, North Carolina + 5 more

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 40
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 27 more

Conditions: Anemia, Sickle Cell
Interventions: Blood draw; Procedure
Lead sponsor: Emory University; Other
Eligibility: 15 Years to 40 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 40
States / cities: Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 28 more

Conditions: Parkinson Disease
Interventions: Coenzyme Q10 with vitamin E, placebo with vitamin E; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 30 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 59
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 48 more

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 3 Months
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 45
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 29 more

Conditions: Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney
Interventions: Bardoxolone methyl; Drug
Lead sponsor: Biogen; Industry
Eligibility: 12 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 61
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 53 more

Conditions: Melanoma
Interventions: Intismeran autogene, Pembrolizumab, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,089 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 34
States / cities: Springdale, Arkansas • Los Angeles, California • San Francisco, California + 27 more

Search by objective public record fields.

A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

Alvocidib Biomarker-driven Phase 2 AML Study

Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)

Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Preventing Acute Chest Syndrome by Transfusion Feasibility Study

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

Greenlight Plus Study: Approaches to Early Childhood Obesity Prevention

Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy

Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout

Chronic Plaque Psoriasis (Ps) Registry

Study of Pregnancy And Neonatal Health (SPAN)

The Safety and Effectiveness of Zidovudine in the Treatment of Patients With Early AIDS Related Complex

STRIDE Biorepository

Effects of Coenzyme Q10 (CoQ) in Parkinson Disease

A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIV

An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)